Trilaciclib (G1T28, 4, Figure 3) is currently ongoing phase II trials in patients with small cell lung cancer (NCT02514447, NTC02499770) and with hormone receptor negative BC (NCT02978716), while entered in phase III for metastatic colorectal cancer (NCT04607668) [50,51,52,53]. This evidence concerns the gene NR4A1 and breast cancer.